AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04908852 — intervention group
Intervention type: OTHER
Intervention: Symptom questionnaires - Observational Study
Description: Symptom questionnaires at baseline, 1-, 2-, 3- and 4-weeks.
Study NCT06560099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: will receive 10 IU oxytocin intravenous bolus over one min and infusion of 10 IU oxytocin in 500 ml of 0.9 saline over four hours.
Study NCT06083259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin sponge stabilization with suture and cyanoacrylate
Description: The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, Ethicon, USA)+ supporting sutures (control group)
Study NCT06241443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: video-modeling
Description: The students in the group had the opportunity to learn through an educational video that followed the Natural Birth Approach Scenario. Afterward, they put their knowledge into practice and were evaluated using the Birth Approach Clinical Skills Guide. A feedback session followed the practice session. Finally, they were assessed using scales to measure their performance.
Study NCT06098547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Patients will undergo liver transplantation according to the standard procedures of the institutional Center's protocol (cadaveric or living donor transplantation, whole or partial liver).~Liver transplantation is preceded by an exploratory laparotomy with clinical evaluation and frozen section examination of lymph nodes in the hepatoduodenal ligament and along the common hepatic artery/celiac axis.
Study NCT05443854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoglycosides intervention
Description: Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines \[3, 28, 50\].~Systematic aminoglycoside therapy using Amikacin at a dose of 25 to 30 mg/Kg per dose, at a rate of a maximum of 1 infusion per day will be delivered.~Recommended duration will be of three days or until microbiological documentation.
Study NCT05443854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lack of protective isolation intervention
Description: Protective isolation will be avoided until ICU discharge is deemed possible. Specific measures regarding nutrition (including avoidance of food consider at risk of fungal contamination) and water protection will be maintained.~Extended universal hygiene measures will be maintained and use of mask will be advocated during viral epidemic periods.~A high degree of compliance as regard to antifungal prophylaxis guidelines and local standard hygiene procedures will be advocated
Study NCT05443854 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No systematic aminoglycosides intervention - standard arm
Description: Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines \[3, 28, 50\].~No systematic aminoglycoside therapy will be provided except in presence of predefined specific organ infection (such intra-vascular infection such endocarditis for example) or drug-resistant infection requiring aminoglycosides.
Study NCT05443854 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Protective isolation intervention - standard arm
Description: Protective isolation will be provided systematically as currently practiced in participating centers. Modality will be in line with recent SRLF guidelines, we will recommend for the patients to receive an isolation the maximal available isolation with the aim to provide:~1. High-efficiency air filtration \[filtration of 99.7% of particles greater than or equal to 0.3 µm; International Organization for Standardization (ISO) class 5 or better\]~2. Geographical isolation in an individual room~3. Technical isolation, including a face mask and a cap. This approach of isolation will however be pragmatic on the basis of the best available level of isolation in line with recommendation, while not delaying ICU admission and patients' care
Study NCT06449664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADT-train
Description: A new training concept is tested on men with prostate cancer receiving androgen deprivation therapy
Study NCT06099483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Action observation and motor imagery
Description: EEG recording was taken while watching a 10-minute video recording of specified breathing exercises and imagining the exercises.
Study NCT06099483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active breathing exercise
Description: EEG recording was taken while the physiotherapist performed active breathing exercises for 10 minutes.
Study NCT06099483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: EEG recording was taken while resting with eyes closed for 10 minutes.
Study NCT06022055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and tissue collection
Description: Blood will be collected for group 1 during (i) the enrolment visit, (ii) in the 24 hours following a seizure, (iii)before the surgery and (iv) in the 36 months following the surgery. The left-over tissue, not useful for diagnostic purpose, will be kept for research.~Blood will be collected for group 2 right before the surgery and in the 36 months following the surgery. The left-over tissue not useful for diagnostic purpose will be kept for research.
Study NCT06083259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin sponge stabilization with cyanoacrylate
Description: Seconder The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, USA) (test group)
Study NCT06558981 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Ppatients would receive external radiation therapy within 6 weeks after surgery, using intensity-modulated radiation therapy (IMRT) or volume modulated radiation therapy (VMAT) techniques. RAI would be administered as standard care. The treatment window is within 6 months after surgery.
Study NCT06558981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: radioiodine treatment
Description: RAI would be delivered based on the condition of residual lesions after surgery. The treatment window is within 6 months after surgery.
Study NCT06558981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radioiodine treatment
Description: RAI would be delivered based on the condition of residual lesions after surgery. The treatment window is within 6 months after surgery.
Study NCT06560749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Measure the impact of physical exercise in the cognition of pacients diagnosed with Bipolar Disorder
Study NCT06562322 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be received placebo PBMT on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
Study NCT06562322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 300 J
Description: Participants will be received PBMT at 300 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
Study NCT06562322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 600 J
Description: Participants will be received PBMT at 600 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
Study NCT06562322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1260 J
Description: Participants will be received PBMT at 1260 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
Study NCT06561867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 MG
Description: Efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects
Study NCT06561867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 MG
Description: Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study NCT04738448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Therapy Group
Description: The art therapy intervention will be executed by the same Medical University of South Carolina (MUSC) board-certified art therapist for each group. The art therapist is a masters-level, licensed practitioner who has experience working in the healthcare system and treating providers. The same art therapy practices that are utilized in daily practice at MUSC will be employed in this study, with a focus on reducing burnout symptoms. Pilot testing of the intervention has been performed informally at MUSC with positive feedback reported by healthcare providers.
Study NCT06560086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 10-6 mol/L ketoconazole, which is the injectable solution powder. Ketoconazole is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
Study NCT06560086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone
Description: A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 1 IU/mL luteinizing hormone, which is the injectable solution powder. Luteinizing hormone is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
Study NCT05175365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance
Description: Each session consists of a 60-minute dance class taught by a professional dancer. Dance classes begin with a seated warm-up with various coordination, rhythm, range of motion, memorization and coordination exercises. The level of difficulty of the exercises increases as the sessions progress. Balance is also an important part of training as well as the feeling of being part of a group, of interacting with each other. The hour ends with stretching in a sitting position.
Study NCT05312112 — intervention group
Intervention type: DRUG
Intervention: Venetoclax
Description: Observational study of venetoclax in AML
Study NCT05312112 — intervention group
Intervention type: DRUG
Intervention: Gilteritinib
Description: Observational study of gilteritinib in AML
Study NCT04970108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Egito
Description: EGITO Egito coated tablet. EMPAGLIFLOZIN PLACEBO Empagliflozin placebo coated tablet. TELMISARTAN PLACEBO Telmisartan coated tablet.
Study NCT04970108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin + telmisartan
Description: Drug: EMPAGLIFLOZIN Empagliflozin 25 mg coated tablet. Drug: TELMISARTAN Telmisartan 40/80 mg coated tablet. EGITO PLACEBO Egito placebo coated tablet.
Study NCT00411658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Device
Study NCT00411658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Study NCT00411658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryopreserved
Study NCT05759312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab 240mg IV every 2 weeks
Study NCT05994183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Dexamethasone 0.6 mg/kg/dose orally (max 16 mg/dose)
Study NCT05759312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin 2000mg PO QD
Study NCT05800366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: human IgG1-bispecific antibody, via IV infusion
Study NCT05800366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab
Description: an antibody drug conjugate (ADC) that contains a humanized IgG1 anti-human CD79b monoclonal antibody, via IV infusion
Study NCT05800366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Per standard care, via IV infusion
Study NCT05800366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Per standard care, via IV infusion
Study NCT05800366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Per standard care, via IV infusion
Study NCT05800366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Per standard care, orally
Study NCT06398288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermal matrix (Oracell, LifeNet, USA)
Description: Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) for 2 minutes + a mixture of anorganic bovine bone (Straumann Xenograft, Straumann) and cortical mineralized/demineralized allograft (Oragraft, Lifenet Health) + dermal matrix on the buccal aspect (Oracell, Lifenet Health)
Study NCT06398288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No dermal matrix
Description: Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) for 2 minutes + a mixture of anorganic bovine bone (Straumann Xenograft, Straumann) and cortical mineralized/demineralized allograft (Oragraft, Lifenet Health)
Study NCT04676776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: All participants receive 1.5 mg levonorgestrel on day 1
Study NCT04676776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: All participants receive 200 mg mifepristone on day 3
Study NCT06053229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percussive massage
Description: 30 minutes of percussive massage will be administered twice per day during the 10 day immobilization period using a percussive massage device
Study NCT06053229 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Leg Immobilization
Description: All subjects will have their left leg immobilized using an immobilization brace for 10 days
Study NCT06053229 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Leg Immobilization
Description: All subjects will have their left leg immobilized using an immobilization brace for 10 days
Study NCT05629442 — intervention group
Intervention type: OTHER
Intervention: ctDNA
Description: initial research biopsy, quality of life assessments and ctDNA collection
Study NCT06355973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using tablets and workbooks cognitive function.
Description: Cognitive training programs corresponding to memory, attention, time and space, and orientation are conducted for 35 to 60 minutes.
Study NCT06355973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: self-programming of physical function training.
Description: The fitness program consisting of stretching, muscle strength, coordination, and aerobic exercise lasts 20 to 30 minutes, and additional 3-4 times/mainly 30 to 40 minutes of aerobic exercise.
Study NCT06492343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI based neurofeedback
Description: participants will receive neurofeedback from their brain in order to modify their own brain function
Study NCT01063933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir
Description: Peramivir is a liquid for parenteral administration. Cohort I: Peramivir, 10 mg/kg intravenously (IV) every day (QD) (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort II: Peramivir 12 mg/kg IV QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort III: Peramivir 16 mg/kg QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Proposed doses for subjects in Cohorts IV, V, VI, and VII are 18, 18, 14 and 12 mg/kg, respectively, IV, QD for 5 days or until hospital discharge, whichever comes first. IV peramivir will be administered over 60 minutes.
Study NCT04706221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CM-1500
Description: Blood volume monitor CM-1500
Study NCT05143775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake craniotomy
Description: Randomly select 30 participants to implement new surgical plan, which is using a monopolar stimulator to determine positive function sites and save tumors within 5 mm of the posterior superior longitudinal fasciculus/arcuate fasciculus
Study NCT05143775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Awake craniotomy
Description: Randomly select 30 participants to implement new surgical plan, which is using a monopolar stimulator to determine positive function sites and save tumors within 5 mm of the posterior superior longitudinal fasciculus/arcuate fasciculus
Study NCT05592691 — intervention group
Intervention type: PROCEDURE
Intervention: Fascial block
Description: The end of the drug infusion will be considered the time zero (T0); subsequently blood samples (4ml) will be taken at pre-established time intervals (after 5, 15, 30, 60, 120 and 180 minutes). Blood samples will be collected in test tubes and centrifuged within 1 hour of collection; subsequently they will be stored at a low temperature and transported to the reference analysis laboratory.
Study NCT05009550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group ESP
Description: Single-shot ultrasound guided ESP block is performed at the T8 vertebral level before the procedure to all patients in ESP block Group
Study NCT05009550 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-blocked Group
Description: This Group is received no intervention.Patients will be sedated as standard and radiofrequency procedure will be applied.
Study NCT05752409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The median dose of esketamine
Description: 1mg•kg-1propofol and 0.5 mg•kg-1esketamine for general anesthesia induction.
Study NCT05752409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The high dose of esketamine
Description: 1mg•kg-1propofol and 0.75 mg•kg-1esketamine for general anesthesia induction.
Study NCT05752409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2mg•kg-1propofol for general anesthesia induction.
Study NCT04949295 — intervention group
Intervention type: DEVICE
Intervention: ocular surface analyzer
Description: Using ocular surface analyzer for Inspection
Study NCT05680701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: real tACS
Description: The participant will receive one session of 10 Hz tACS for 20-minutes
Study NCT05680701 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham tACS
Description: The participant will receive one session of active-sham tACS for 20-minutes
Study NCT05619341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: psyllium
Description: psyllium 20g
Study NCT05619341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: inulin
Description: long chain fructan
Study NCT05619341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: inulin
Description: long chain fructan
Study NCT05920265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum plain Block
Description: ultrasound guided Quadratus Lumborum plain Block using 0.5 ml/kg bupivacaine 0.25% .
Study NCT05920265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fascia iliaca block
Description: ultrasound guided fascia iliaca block using 0.5 ml/kg bupivacaine 0.25%
Study NCT05920265 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: no intervention
Study NCT06018168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skincare Routine
Description: Morning:~1. GENTLECLEAN - Wash with a quarter-sized amount of lukewarm water. Pat skin dry after.~2 CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin 3. YOUARESUNSHINE - Apply generously and evenly as the last step in the skincare routine (before makeup).~Night:~1. VITAMINSCRUB - Wet your face with lukewarm water \& apply a quarter-sized amount to wet palms. Lather until foamy. Gently massage the scrub using circular motions for 5-10 seconds. Rinse with lukewarm water and pat dry.~2. CLEARITY - Apply 2-3 pumps and massage into the skin avoiding the eye area. Let sit for 10-15 minutes. Do not wash off.~3. CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin~4. HYDRAGLOW - Apply a dime-size amount of lotion and massage into the face
Study NCT06018168 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MINDBODYSKIN Supplement
Description: Participants will take 3 capsules daily with a meal. The MINDBODYSKIN acne supplement contains Vitamin A (6,100mcg per serving of 3 capsules), Vitamin B12, Vitamin B-5, 5-Hydroxytryptophan (5-HTP), 3,3'-Diindolymethane (DIM), a proprietary liver blend of milk thistle, dandelion extract and L-glutathione, turmeric root extract, a proprietary digestive blend of protease and betaine hydrochloride, and silicon dioxide.
Study NCT06433726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BY101921 tablets
Description: An oral PARP7 Inhibitor